Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

Mercedes Unzeta; Elisenda Sanz

doi:10.1016/B978-0-12-386467-3.00011-X

Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

Mercedes Unzeta, Elisenda Sanz

Research output: Chapter in Book › Chapter › Research › peer-review

5 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. In our search for compounds able not only to extend the effects of dopamine by preventing its degradation but also to halt or slow the neurodegenerative process, we designed, synthesized, and biologically tested a series of propargylamines for their potential use as therapeutic agents for PD. Among them, PF9601N, [. N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD. In this chapter, we describe the preclinical evidence revealing the novel MAO-BI PF9601N as an interesting candidate for the treatment of PD. © 2011 Elsevier Inc.

Original language	English
Title of host publication	International Review of Neurobiology
Pages	217-236
Number of pages	19
Volume	100
DOIs	https://doi.org/10.1016/B978-0-12-386467-3.00011-X
Publication status	Published - 1 Jan 2011

Keywords

Antiapoptotic compounds
MAO-B inhibitor
Neuroprotection
PF9601N
Parkinson's disease
Propargylamines

Access to Document

10.1016/B978-0-12-386467-3.00011-X

Fingerprint Dive into the research topics of 'Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease'. Together they form a unique fingerprint.

Cite this

@inbook{05277e6e55434541b760941b255b5fca,

title = "Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease",

abstract = "Parkinson's disease (PD) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. In our search for compounds able not only to extend the effects of dopamine by preventing its degradation but also to halt or slow the neurodegenerative process, we designed, synthesized, and biologically tested a series of propargylamines for their potential use as therapeutic agents for PD. Among them, PF9601N, [. N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD. In this chapter, we describe the preclinical evidence revealing the novel MAO-BI PF9601N as an interesting candidate for the treatment of PD. {\textcopyright} 2011 Elsevier Inc.",

keywords = "Antiapoptotic compounds, MAO-B inhibitor, Neuroprotection, PF9601N, Parkinson's disease, Propargylamines",

author = "Mercedes Unzeta and Elisenda Sanz",

year = "2011",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-386467-3.00011-X",

language = "English",

isbn = "0074-7742",

volume = "100",

pages = "217--236",

booktitle = "International Review of Neurobiology",

}

TY - CHAP

T1 - Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

AU - Unzeta, Mercedes

AU - Sanz, Elisenda

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Parkinson's disease (PD) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. In our search for compounds able not only to extend the effects of dopamine by preventing its degradation but also to halt or slow the neurodegenerative process, we designed, synthesized, and biologically tested a series of propargylamines for their potential use as therapeutic agents for PD. Among them, PF9601N, [. N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD. In this chapter, we describe the preclinical evidence revealing the novel MAO-BI PF9601N as an interesting candidate for the treatment of PD. © 2011 Elsevier Inc.

AB - Parkinson's disease (PD) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. In our search for compounds able not only to extend the effects of dopamine by preventing its degradation but also to halt or slow the neurodegenerative process, we designed, synthesized, and biologically tested a series of propargylamines for their potential use as therapeutic agents for PD. Among them, PF9601N, [. N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD. In this chapter, we describe the preclinical evidence revealing the novel MAO-BI PF9601N as an interesting candidate for the treatment of PD. © 2011 Elsevier Inc.

KW - Antiapoptotic compounds

KW - MAO-B inhibitor

KW - Neuroprotection

KW - PF9601N

KW - Parkinson's disease

KW - Propargylamines

U2 - 10.1016/B978-0-12-386467-3.00011-X

DO - 10.1016/B978-0-12-386467-3.00011-X

M3 - Chapter

SN - 0074-7742

VL - 100

SP - 217

EP - 236

BT - International Review of Neurobiology

ER -